Ezetimibe + Atorvastatin — Competitive Intelligence Brief

Ezetimibe + Atorvastatin (Ezetimibe + Atorvastatin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor (statin combination). Area: Cardiovascular.

marketed Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor (statin combination) NPC1L1 (ezetimibe); HMG-CoA reductase (atorvastatin) Cardiovascular Small molecule

Target snapshot

Ezetimibe + Atorvastatin (Ezetimibe + Atorvastatin) — Organon and Co. This combination reduces cholesterol by blocking intestinal cholesterol absorption (ezetimibe) and inhibiting HMG-CoA reductase to decrease hepatic cholesterol synthesis (atorvastatin).

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ezetimibe + Atorvastatin TARGET	Ezetimibe + Atorvastatin	Organon and Co	marketed	Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor (statin combination)	NPC1L1 (ezetimibe); HMG-CoA reductase (atorvastatin)
Ezetimibe/Rosuvastatin	Ezetimibe/Rosuvastatin	Addpharma Inc.	marketed	Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor (statin combination)	NPC1L1 transporter (ezetimibe); HMG-CoA reductase (rosuvastatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor (statin combination) class)

1. Addpharma Inc. · 1 drug in this class
2. Organon and Co · 1 drug in this class